Clinical Trial Update: Anti-Tac for Treatment of Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of Phase 1 and Phase 2 clinical trials of Anti-Tac (muromonab-CD3) for HTLV-1 infection and T-cell leukemia, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Htlv-1 Infection
• T-cell Leukemia

Drugs mentioned

• Anti-Tac (muromonab-CD3)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HTLV-I Infection, T Cell Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-08-09